Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Volker Stieber

Radiation Oncology Winston Salem, NC Medical Doctor

NPI 1609858661 CMS profile 208390

3333 Silas Creek Pkwy, Winston Salem, NC 27103

Open in the dashboard

General payments

$99,448

210 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$252,882 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Volker Stieber of Winston Salem, NC is reported in the CMS Open Payments database as having received $99,448 across 210 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $252,882 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Radiation Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,205 4
2024 General $8,026 15
2023 General $8,060 24
2022 General $11,057 19
2021 General $7,013 13
2020 General $23,524 37
2019 General $38,563 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Volker Stieber
  • Radiation Oncology median
  • Middle half of Radiation Oncology
  • National median

In program year 2025, general payments to Volker Stieber were reported at $3,205. Among 3,409 Radiation Oncology profiles paid that year, the median was $172 and the middle half received between $61 and $514.

Show as a table
Year Volker Stieber Radiation Oncology median Middle half National median
2019 $38,563 $138 $48–$462 $163
2020 $23,524 $79 $26–$262 $114
2021 $7,013 $119 $37–$358 $132
2022 $11,057 $139 $43–$424 $149
2023 $8,060 $167 $57–$473 $160
2024 $8,026 $168 $56–$541 $164
2025 $3,205 $172 $61–$514 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novocure Inc. $99,141 193 payments
  2. AstraZeneca Pharmaceuticals LP $180 3 payments
  3. Varian Medical Systems, Inc. $38 2 payments
  4. Arbor Pharmaceuticals, Inc. $38 9 payments
  5. Brainlab, Inc. $25 1 payment
  6. AngioDynamics, Inc. $13 1 payment
  7. Bayer HealthCare Pharmaceuticals Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $48,050 27 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $24,150 14 payments
  3. Travel and Lodging $15,418 81 payments
  4. Consulting Fee $6,850 5 payments
  5. Food and Beverage $4,942 74 payments
  6. Education $38 9 payments
Products named General payments · program years 2019–2025
  1. Oncology $61,960 121 payments
  2. Optune Oncology $26,103 55 payments
  3. Optune Oncology $6,905 13 payments
  4. Optune Gio $3,025 1 payment
  5. Gliadel $33 8 payments
  6. Edge $22 1 payment
  7. TrueBeam $16 1 payment
  8. Xofigo $12 1 payment
  9. Horizant $5 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

64

Median for Radiation Oncology: 65

Drug cost

$1,579

Median for Radiation Oncology: $978

Branded share of claims

20.3%

Median for Radiation Oncology: 7.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dexamethasone Generic 26 $844
Sucralfate Generic 25 $426
Lidocaine Hcl Viscous Lidocaine Hcl Brand 13 $309

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,680 Part D prescribers listed as Radiation Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$149,646

Medicare's payments for the services billed

Medicare patients

266

Average age 74

Services billed

1,871

149 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 75%
Arthritis 48%
Ischemic heart disease 47%
COPD 32%
Diabetes 29%
Depression 28%
Chronic kidney disease 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

210 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Radiation Oncology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record